NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. It markets its proprietary therapy, Tumor Treating Fields (TTFields), that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die. The TTFields therapy is used as a monotherapy treatment for adult patients with glioblastoma brain cancer and malignant pleural mesothelioma. The company is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and gastric cancer.